It has been shown that dyslipidemia is related to bone mineral density and fragility. Hypolipemiant drugs as statins or fi brates seem to increase the bone mineral density and probably to protect against fractures. The question that arises in this context is whether statins or fi brates have a positive effect on bone fracture repair process and which is their behaviour in an osteoporotic context. Our objective was to study the incidence of osteoporosis, dyslipidemia and of the association of these diseases, and to compare the effect of statins and fi brates on fracture repair in experimental conditions. Material and method: We studied the incidence of dyslipidemia and osteoporosis in the activity of a private family medicine cabinet. In the experimental part we observed from a radiographic point of view the fracture repair process of rats' femurs. We analyzed 6 subgroups of 12 rats each: (1) ovariectomized control, (2) ovariectomized treated with statins, (3) ovariectomized treated with fi brates, (4) nonovariectomized control, (5) ) nonovariectomized treated with statins, (6) ) nonovariectomized treated with fi brates. The radiographic aspect has been objectifi ed with a score at 2, 4, 6 and 8 weeks.
Introduction
Osteoporosis is a disease represented by excessive loss of bone mass and a risk factor for fractures. According to WHO report for 2006, osteoporosis is an important problem of public health. 1700 fractures on osteoporotic bone happen daily (650 000 per year) in the European Union [1] .
Osteoporosis and dyslipidemia are diseases associated with old age. Age, sedentary life style and estrogen deficiency are common risk factors for the two diseases. Th ere are numerous reasons to search a proof that there is an association between bone mineral density and lipid profi le [2] . Dyslipidemia has been associated with bone mass and fragility, and it could be a risk factor for osteoporosis [2] [3] [4] [5] [6] , which suggests the importance of treating dyslipidemia in order to prevent osteoporosis and subsequent fractures.
In addition, therapeutic agents for osteoporosis have antiatherosclerotic properties, and molecules such as statins and fi brates, hypolipemiants, seem to increase bone mass and even protect against fractures [7] [8] [9] [10] [11] . Experimental studies showed a positive eff ect of treatment with statins in the fracture repair process [12] [13] [14] [15] . Regarding the eff ect of fi brates on fracture repair process, there are signifi cantly less studies [11] .
In this context the questions arise whether statins or fibrates have a comparable positive eff ect on fracture healing process and which is their behaviour in an osteoporotic context, so that we could be able to choose a treatment which could act in a polyvalent way, for the patient's benefi t.
Material and method
Th e fi rst part of the study contains a statistical analysis on the incidence of osteoporosis and dyslipidemia in a private family medicine practice, during the National Program for the Evaluation of Public Health.
Th e study comprises 646 patients investigated between 2007-2010. Th e analyzed parameters were: sex, age, osteoporosis, dyslipidemia, hepatopathy, antiosteoporotic and hypolipemiant treatment. Th e inclusion criteria were: presence of rheumatologically diagnostised osteoporosis or Due to the fact that in our clinical study the hypolipemiant treatment was diverse, which did not allow pertinent comparisons, we used an experimental model to evaluate and to compare the eff ect of the hypolipemiant medication on bone remodelling. For this purpose we chose the most frequently used active substances among our patients' medication, simvastatine and fenofi brate.
For the experiment part of the study we used 72 Albino Wistar rats, all adult females, 16 to 18 months of age (human correspondent: women from 47 to 52 years of age, the period around menopause), weighing on average 300 grams. Th e Ethics Committee of the University of Medicine and Pharmacy of Tîrgu Mureș approved the treatment and study protocols with document number 2/2009. Th e animals were divided into 2 groups: nonovariectomized rats (NOVX) and ovariectomized rats (OVX) ( Table I) .
For all surgical interventions the animals were anesthetized with an intraperitoneal injection of ketamine and xiline (4-5 mg/kg). All animals suff ered a mediodiaphisary fracture to the right femur that was stabilized with an intramedullary rod. In the OVX groups the fracture was made at 12 weeks postovariectomy.
Groups 2 and 5 received a daily dose of simvastatin 10 mg/kg and groups 3 and 6 received fenofi brate 10 mg/ kg. At 2, 4, 6 and 8 weeks postfracture radiographies were made in order to evaluate the healing process. To quantify the changes at the fracture site we used a radiographic score (Table II) .
In order to evaluate the global eff ect on fracture healing process we used a personal algorithm: we made a ranking Table II . Radiographic scoring system, adapted after Akman et al. [16] Score In case of equality between two subgroups, each received the average of the unallocated scores (e.g. if a subgroup received 1 point and the other two groups had a similar aspect, each of them received 2.5 points).
Results

A. Clinical results
From the 646 patients included in our database, 555 were female (85.91%). Osteoporosis alone was identifi ed in 152 patients (23.53%), dyslipidemia alone in 193 patients (29.87%) and the association between these two diseases in 301 patients (46.60%). Among the patients with dyslipidemia 61.65% (119 patients) were women, representing 21.44% of all women included in this study. In the 51-60 years age group there were 46 female patients (38.66% of women with dyslipidemia) (Figure 1 ).
Among female patients with dyslipidemia, 8 (6.72%) were under treatment with statins, 1 (0.84%) under treatment with fi brates, 1 (0.84%) on statins and fi brates and 109 (91.59%) had no hypolipemiant treatment (Figure 2 ).
In the group of patients with osteoporosis 90.13% (137 persons) were women, representing 24.68% of all women included in the study. Th e maximum incidence was in the sixth decade for women, 54 patients (39.42%), and for men in the seventh decade, 6 cases (40%) (Figure 3 ). Seventy-nine women (57.66%) diagnosed with osteoporosis had an antiosteoporotic treatment. Th e patients with dyslipidemia and osteoporosis were, in majority, represented by women, 299 (99.34% of patients with both diseases). Th e maximum incidence of the association of the two diseases was in the sixth decade, 116 patients (38.8%), followed by fi fth and seventh decades with 80 patients each (26.76%) (Figure 4 ).
Female patients' treatment was as it follows: 149 (49.83%) had only an antiosteoporotic treatment, 70 (23.41%) had no treatment and 44 (14.72%) had an associated treatment represented by statins and antiosteoporotic treatment ( Figure 5) .
Out of 418 women with dyslipidemia or dyslipidemia 
B. Experimental results
Two weeks post fracture, the subgroups of NOVX group showed the same status of evolution of the healing process, respectively callus formation ( Figure 7A ,B,C). Th e same healing synchronisation was observed at 4 weeks ( Figure 8A ,B,C). But at 6 weeks, the NOVX subgroup treated with statins ( Figure 9B ) was completely consolidated, while NOVX subgroup treated with fi brates ( Figure  9C ) and NOVX control subgroup ( Figure 9A ) were still at the callus formation stage. Th e last evaluation at 8 weeks showed a complete healing in NOVX subgroup treated with statins ( Figure 10B ) the disappearance of fracture line in the NOVX control subgroup ( Figure 10A ) and the NOVX subgroup treated with fi brates ( Figure 10C ) was still in the formation of callus stage. At two weeks the OVX subgroup treated with statins ( Figure 7E ) presented already the onset of bony union, the OVX control subgroup ( Figure 7D ) began the callus formation, while in the OVX subgroup treated with fi brates (Figure 7F ) the callus formation process was not initiated. At 4 weeks, the radiographic aspect of the OVX control subgroup ( Figure 8D ) and of the OVX subgroup treated with statins ( Figure 8E ) was similar, showing the onset of bony union, the OVX subgroup treated with fi brates ( Figure 8F ) did not begin the healing process. At 6 weeks, the OVX control subgroup ( Figure 9D ) and the OVX subgroup treated with statins ( Figure 9E ) has the same aspect as at 4 weeks, and the OVX subgroup treated with fi brates ( Figure 9F ) began the callus formation. Finally, at 8 weeks, the OVX subgroup treated with statins ( Figure 10E ) was completely healed, while the OVX subgroup treated with fi brates (Figure 10F) showed an onset of bony union, having a similar aspect with the OVX control subgroup (Figure10D) .
Comparing the subgroups of the OVX group, we had the following results: subgroup 1 -7 points, group 2 -11 points and group 3 -4.5 points. In the case of the NOVX subgroups, the scores were: subgroup 4 -7.5 points, subgroup 5 -10 points and subgroup 6 -6.5 points.
Discussions
Osteoporosis and dyslipidemia are diseases that mainly affect the population aged more that 50 years old, leading to an increased morbidity and mortality. It is estimated that osteoporosis aff ects one of three women after menopause, especially after the age of 65. In the population studied by us, 89.6% of women over 60 years old were aff ected by osteoporosis. In an EU report it is estimated that the number of women over 65 years old will increase to 26.4 million by 2050 [20] .
A series of clinical studies examined the relation between dyslipidemia and bone mineral density (BMD) but the results were controversial [3] [4] [5] [6] [17] [18] [19] . Th ese observations added to the common risk factors for dyslipidemia and osteoporosis could be the explanation for the increased incidence of their association. In our study, the number of patients suff ering of both diseases was greater than the number of patients having only one of them. Considering the correlation between the two diseases and our results showing that dyslipidemia precedes osteoporosis (maximum incidence in the 5 th decade versus the 6 th decade) a hypothesis rises of a causal relation between the two pathologies. Knowing that women with an LDL-C higher than 160 ml/dl have a two-fold probability to suff er of osteopenia than women with a normal LDL-C [4] and that dyslipidemic patients, regardless of their gender, have an intensifi ed bone turnover [5] , new ideas for bone loss prevention and subsequent fractures appear.
After the identifi cation of some molecular interferences between the two diseases, the behaviour of hypolipemiant treatment (with statins and fi brates) in an osteoporotic context has been experimentally evaluated. Some of these studies focused on the interference of these molecules with the fracture healing process, a major complication of osteoporosis. On a global level, a women's risk to suff er an osteoporotic fracture is of 40% [20] .
Biphosphonates, the main treatment for osteoporosis, act a step below statins in the metabolic pathway of mevalonate [21] . Th erefore, more and more evidence indicates the fact that these two therapeutic classes modulate at the same time osteoporosis and dyslipidemia. In experimental studies a better callus formation was showed in animals treated with statins in comparison to control group [12] [13] [14] [15] . Our results are consistent with these studies, even though diff erent means of evaluating fracture healing were used.
On the other hand, fi brates stimulate osteoblast differentiation and proliferation. By intensely stimulating ARNm for type I collagen, it leads to bone matrix formation. However, there is little information regarding treatment with fi brates in an osteoporotic context and in correlation with fractures [5] .
Our experimental model show the benefi cial eff ect that statins have on fracture healing formation on healthy and pathological bone (osteoporotic), the osteogenic eff ect being more precocious on osteoporotic bone. Fibrates play a role in inducing callus formation, their eff ect is favoured by a decreased estrogens level, but they delay the bone consolidation both on healthy and pathological bone.
Conclusions
Th e maximum incidence for osteoporosis, dyslipidemia and their association is superposable, that is the 5 th , 6 th and 7 th decades, with a peak in the 5 th decade for dyslipidemia and in the 6 th decade for osteoporosis and the association of the two diseases.
Th e higher incidence of the association between the two diseases, followed by the incidence of dyslipidemia in comparison to the osteoporosis incidence brings arguments to the necessity of choosing a hypolipemiant treatment that has, at the same time, a protective eff ect on bone.
In the case of women, the incidence of these disease change their proportion, osteoporosis having a higher incidence than dyslipidemia not associated to osteoporosis. Th e percent of 78.46% represented by female patients with an associated pathology or only with dyslipidemia, with an exclusive antiosteoporotic treatment or without any treatment is the target group for optimizing the hypolipemiant treatment.
Hypolipemiant treatment infl uences the callus formation process. Th e eff ect of statins is more important on the OVX group, while for fi brates we can observe the opposite phenomenon, with a more accentuated eff ect on the NOVX group and that indicates the interference of hypolipemiant treatment with estrogens level. Th e treatment with fi brates delays callus formation, the scores of OVX subgroup treated with fi brates and of NOVX subgroup treated with fi brates being inferior to those of control subgroups.
Having an important incidence, osteoporosis needs the elaboration of treatment protocols for dyslipidemia that can not only decrease the cardiovascular risk but also the risk of complications of osteoporosis. We support the adjuvant eff ect of the treatment with statins in the fracture healing process, superior to the treatment with fi brates.
